These findings were further validated in independent cohorts and AIDS Malignancy Consortium trials, supporting CXCL10 as both an early biomarker and a predictor of poor outcomes in HIV-NHL [57,60]. Here, CXCL10 is linked to non-Hodgkin lymphoma.